Text Size

Use of Bone Scintigraphy, CT and MRI in Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by University of Aarhus.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT00682253
First received: May 20, 2008
Last updated: September 8, 2009
Last verified: September 2009
History of Changes
  Purpose

A new imaging modality combining CT and tomographic bone scintigraphy (SPECT/CT) has enabled the combination of functional and anatomical imaging. Its use in cancer patients has not yet been evaluated or validated against a relative gold stand or clinical follow up. The purposes of this study are: 1: to validate the use of conventional planar bone scintigraphy and SPECT combined with low-dose or diagnostic CT and compare this to 3 Tesla MRI and clinical follow up. 2: to compare the specificity of low-dose and diagnostic CT, respectively, combined with bone SPECT. 3: to construct an algorithm for optimal evaluation of disease dissemination in breast cancer patients


Condition
Breast Neoplasms

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Use og Bone Scintigraphy, CT and MRI for Detection of Metastases in Patients With Breast Cancer

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Aarhus:

Estimated Enrollment: 180
Study Start Date: May 2008
Estimated Study Completion Date: March 2011
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

women aged 18-80 years with suspicision of disseminated breast cancer seen at Dept. of Oncology, Aarhus University Hospital

Criteria

Inclusion Criteria:

  • Histological verified breast cancer
  • Age 18-80 years
  • Investigation for metastases using imaging modality/modalities planned
  • Written consent to participate in trial

Exclusion Criteria:

  • Overweight limiting the use of MRI
  • Metal parts in body
  • Claustrophobia
  • Allergy to contrast agents used in trial
  • Pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00682253

Contacts
Contact: Anni Eskild-Jensen, MD, PhD, DMSci +45 8949 2251 aej@ki.au.dk

Locations
Denmark
Aarhus University Hospital Recruiting
Aarhus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
  More Information

No publications provided

Responsible Party: Anni Eskild-Jensen, Aarhus University Hospital
ClinicalTrials.gov Identifier: NCT00682253     History of Changes
Other Study ID Numbers: SKF-0805
Study First Received: May 20, 2008
Last Updated: September 8, 2009
Health Authority: Denmark: The Regional Committee on Biomedical Research Ethics

Keywords provided by University of Aarhus:
SPECT/CT
MRI
Breast neoplasms

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on May 23, 2013